Navis Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Navis Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-750	Closed	-$788K	–	109
2024 Q3	$788K	Hold	750	–	–	0.85%	25
2024 Q2	$788K	Buy	750 +150	+25%	+$145K	0.9%	22
2024 Q1	$577K	Sell	600 -520	-46%	-$494K	0.69%	35
2023 Q4	$984K	Sell	1,120 -150	-12%	-$124K	1.28%	15
2023 Q3	$1.05M	Buy	1,270 +5	+0.4%	+$3.93K	1.51%	14
2023 Q2	$909K	Hold	1,265	–	–	0.83%	18
2023 Q1	$1.04M	Buy	+1,265	New	+$954K	1.14%	15

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Navis Wealth Advisors's REGN Position: Q4 2024 in Review

Navis Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 750 shares — an estimated $788K sold.

Navis Wealth Advisors first reported a position in REGN in Q1 2023 and held it in 7 quarters. The position peaked at $1.05M in Q3 2023. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Navis Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Navis Wealth Advisors sold 750 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $788K.
Navis Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 7 quarters.
Navis Wealth Advisors's Regeneron Pharmaceuticals position peaked at $1.05M in Q3 2023.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Navis Wealth Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.